Pulmonary Fibrosis Foundation, Celgene Form Biomarker Consortium
The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.
NIH Launches Parkinson's Disease Research Partnership
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
Abbott Receives FDA Approval for IDH2 Mutation CDx Alongside AML Drug
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.